Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental pill aims to shield the liver during cancer treatment

NCT ID NCT06478719

Recruiting now Disease control Sponsor: Febico Biomedical Corp. Source: ClinicalTrials.gov ↗

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This trial tests whether an experimental drug called FB-1603 can protect liver function in people with liver cancer who are receiving a standard procedure called transarterial chemoembolization (TACE). Participants take either a low dose, a high dose, or a placebo capsule daily for 10 weeks. The study measures changes in liver enzyme levels to see if FB-1603 reduces liver damage caused by the cancer treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental oral drug called FB-1603
What this could lead to
If it works, FB-1603 could help preserve liver function during chemoembolization, potentially improving outcomes for liver cancer patients.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not confirm benefit. Liver function changes are measured by blood tests, not long-term survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Linkou Chang Gung Memorial Hospital

    RECRUITING

    Taoyuan, Taiwan, 333, Taiwan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • National Taiwan University Hospital

    RECRUITING

    Taipei, Taiwan, 10002, Taiwan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.